Copper for Neurological Health

Copper is the catalytic atom in dopamine beta-hydroxylase (DBH), the enzyme inside synaptic vesicles of noradrenergic neurons and adrenal chromaffin cells that converts dopamine to norepinephrine. Copper deficiency literally blocks norepinephrine synthesis. Copper is also the catalytic atom in tyrosinase, the rate-limiting enzyme of melanin synthesis (the pigment of the substantia nigra, the eye, and the skin). And copper is required for myelin formation through several less-direct mechanisms, including cytochrome c oxidase (oligodendrocytes have very high mitochondrial demand), peptidylglycine alpha-amidating monooxygenase (PAM, which amidates neuropeptide hormones), and ceruloplasmin-mediated iron handling in oligodendrocytes. The clinical syndromes that result from copper deficiency in the nervous system are dramatic and consequential: copper-deficiency myelopathy (an acquired adult syndrome from zinc overdose, denture cream, or bariatric surgery that almost perfectly mimics Vitamin B12 subacute combined degeneration), Menkes disease (the X-linked infantile encephalopathy from ATP7A loss-of-function), aceruloplasminemia (brain iron overload from inadequate ferroxidase activity), and the proposed contribution of copper dyshomeostasis to Alzheimer disease and Parkinson disease. This page walks through the mechanisms, the syndromes, the diagnostic workup, and the treatment of copper's role in neurological health.

Table of Contents

  1. Dopamine Beta-Hydroxylase — Copper and Norepinephrine Synthesis
  2. Tyrosinase — Melanin Synthesis and Neuromelanin
  3. Myelin, Cytochrome c Oxidase, and Oligodendrocyte Energy
  4. Peptidylglycine Alpha-Amidating Monooxygenase (PAM)
  5. Copper-Deficiency Myelopathy — the Acquired Adult Syndrome
  6. Zinc-Induced Copper Deficiency (Supplement, Denture Cream)
  7. Post-Bariatric Copper Deficiency Myelopathy
  8. Mimicking B12 Subacute Combined Degeneration
  9. Menkes Disease Neurology
  10. Copper, Alzheimer Disease, and Parkinson Disease
  11. Diagnosis and Treatment
  12. Key Research Papers
  13. Connections

Dopamine Beta-Hydroxylase — Copper and Norepinephrine Synthesis

Dopamine beta-hydroxylase (DBH, EC 1.14.17.1) is a copper-dependent monooxygenase that catalyzes the hydroxylation of dopamine at the beta carbon to produce norepinephrine. The reaction is:

dopamine + ascorbate + O&sub2; → norepinephrine + semidehydroascorbate + H&sub2;O

DBH is a homotetramer of 290 kilodaltons total, expressed exclusively in the dense-core vesicles of noradrenergic and adrenergic neurons (locus coeruleus, lateral medullary tegmentum, sympathetic ganglia) and the chromaffin cells of the adrenal medulla. Each subunit contains two catalytic copper atoms (CuA and CuB) and uses ascorbate (Vitamin C) as the electron donor — one of the clearest examples in human biochemistry of a direct Vitamin-C-and-copper enzymatic partnership.

The location of DBH inside synaptic vesicles is significant. Dopamine is synthesized in the cytosol by aromatic amino acid decarboxylase (DDC, converting L-DOPA to dopamine), then packaged into vesicles by the vesicular monoamine transporter VMAT2. Inside the vesicle, the acidic pH and presence of ascorbate plus the copper-dependent DBH convert dopamine to norepinephrine before exocytotic release at the synapse. In noradrenergic neurons (and adrenal chromaffin cells producing epinephrine), this DBH step is essential — without it, the vesicles release dopamine where norepinephrine should appear.

Copper deficiency reduces DBH activity (because newly synthesized DBH cannot be loaded with copper), reducing norepinephrine production. The clinical consequences are subtle in mild deficiency but include autonomic dysfunction (orthostatic hypotension, hypothermia), cognitive slowing (locus coeruleus norepinephrine is essential for vigilance and attention), and depression-like symptoms (reduced central noradrenergic drive). In Menkes disease, the DBH failure contributes to the hypothermia, hypotonia, and feeding difficulties of the affected infant.

The very rare genetic syndrome of congenital DBH deficiency (loss-of-function mutations in the DBH gene itself) produces a clean phenotype of severe orthostatic hypotension from birth, with detectable dopamine in plasma but virtually undetectable norepinephrine. The treatment is L-DOPS (droxidopa), a synthetic precursor that bypasses the DBH step and is decarboxylated directly to norepinephrine. The genetic DBH-deficient patients prove the absolute requirement for the copper-containing enzyme.

Back to Table of Contents

Tyrosinase — Melanin Synthesis and Neuromelanin

Tyrosinase (EC 1.14.18.1) is a copper-dependent oxidase that catalyzes the first two steps of melanin synthesis:

  1. Hydroxylation of tyrosine to L-DOPA (the rate-limiting step)
  2. Oxidation of L-DOPA to dopaquinone

Tyrosinase contains two copper atoms (CuA and CuB) in its active site, both essential for catalysis. Loss-of-function tyrosinase mutations are the most common cause of oculocutaneous albinism type 1 (OCA1), which is characterized by absence of melanin in skin, hair, and eyes from birth. OCA1 patients have nystagmus, photophobia, severely reduced visual acuity, and white-to-pale-yellow hair with pale skin and blue or violet irises.

In Menkes disease (ATP7A loss-of-function, systemic copper deficiency), tyrosinase fails because the apoprotein cannot be loaded with copper in the trans-Golgi network. The Menkes infant has the characteristically pale skin and lustreless hair of tyrosinase deficiency, alongside the connective-tissue and neurologic failures from the other copper-dependent enzymes.

In the brain, a related pigment called neuromelanin accumulates in the dopaminergic neurons of the substantia nigra pars compacta and the noradrenergic neurons of the locus coeruleus. Neuromelanin is not synthesized by tyrosinase (it is produced by spontaneous oxidation of dopamine and norepinephrine and accumulates in autophagic vacuoles), but it does contain copper, iron, and other transition metals bound to its melanin scaffold. The loss of neuromelanin-containing neurons is the pathognomonic feature of Parkinson disease, and the iron and copper bound to neuromelanin in surviving neurons has been proposed as a contributor to the oxidative stress of the dopaminergic neurodegeneration process — see the section on Alzheimer and Parkinson disease below.

Back to Table of Contents

Myelin, Cytochrome c Oxidase, and Oligodendrocyte Energy

Myelin — the lipid-rich insulating sheath wrapped around axons by oligodendrocytes (in the central nervous system) and Schwann cells (in the peripheral nervous system) — depends on copper indirectly through several mechanisms. The most important is the very high mitochondrial energy demand of oligodendrocytes, which synthesize and maintain an enormous mass of myelin membrane per cell. Cytochrome c oxidase (complex IV of the mitochondrial electron transport chain) is the terminal enzyme of oxidative phosphorylation and contains two copper atoms (CuA and CuB) plus heme a and heme a3. Copper deficiency reduces COX activity, impairs ATP generation in oligodendrocytes, and contributes to the demyelination of copper-deficiency myelopathy.

A second, more direct mechanism involves ceruloplasmin and brain iron handling. Iron is required for oligodendrocyte differentiation and myelin synthesis (the iron-containing enzymes of cholesterol synthesis and fatty-acid desaturation are essential for the lipid biosynthesis that builds myelin). Brain ceruloplasmin (a GPI-anchored membrane form, distinct from the soluble plasma form) is expressed by astrocytes and is required for proper iron handling in the brain. Aceruloplasminemia produces brain iron overload with neurodegeneration, while copper deficiency reduces brain ceruloplasmin activity and impairs iron mobilization to oligodendrocytes.

The third mechanism involves the longstanding observation that copper-deficient animals (sheep, cattle) develop a demyelinating syndrome called "enzootic ataxia" or "swayback" — named for the rear-limb weakness and ataxia of affected lambs. The syndrome shares pathophysiologic features with human copper-deficiency myelopathy and provided the early veterinary literature that informed the human clinical description.

Back to Table of Contents

Peptidylglycine Alpha-Amidating Monooxygenase (PAM)

Peptidylglycine alpha-amidating monooxygenase (PAM) is a less-famous but biologically important copper-dependent enzyme that performs the C-terminal amidation of a wide range of bioactive neuropeptides and peptide hormones. Many neuropeptides require C-terminal amidation for full biological activity, including:

PAM contains one copper atom and uses ascorbate as the cofactor (like DBH). Severe copper deficiency reduces PAM activity, which can theoretically contribute to subtle endocrine and neuropeptide dysregulation in copper-deficient patients. The clinical signal is hard to isolate because PAM affects so many hormone systems, but it is part of the broader picture of why copper deficiency produces such polyphenotypic disease.

Back to Table of Contents

Copper-Deficiency Myelopathy — the Acquired Adult Syndrome

The most clinically important neurologic manifestation of copper deficiency in adults is copper-deficiency myelopathy, first systematically characterized by Schleper and Stuerenburg (2001), Kumar and colleagues at Mayo Clinic (2003 onward), and Jaiser and Winston (2010 review). The syndrome typically presents in the fifth to seventh decade of life with:

MRI of the spinal cord often shows characteristic T2 hyperintensity in the posterior columns of the cervical and upper thoracic cord — the same imaging finding seen in Vitamin B12 subacute combined degeneration. The radiologic resemblance is the source of the most common diagnostic pitfall: assuming the patient has B12 deficiency and treating with B12, while the actual etiology is copper.

Back to Table of Contents

Zinc-Induced Copper Deficiency (Supplement, Denture Cream)

The most common cause of copper-deficiency myelopathy in adults in the developed world is chronic zinc overdose. Zinc and copper compete for absorption through the intestinal metallothionein system — high luminal zinc induces large amounts of metallothionein in the enterocyte, and the metallothionein then preferentially binds incoming copper and prevents its export into the portal circulation. The sequestered copper is shed with the enterocyte at the end of its lifespan, producing a steady drain of body copper.

The risk threshold is roughly 50 mg/day of supplemental zinc sustained over months to years. The common settings include:

The clinical workup in any adult with the myelopathy phenotype should always include serum zinc alongside copper and ceruloplasmin. Elevated zinc with low copper is essentially diagnostic of the zinc-induced syndrome, and identifying the zinc source and stopping it is the first step of treatment.

Back to Table of Contents

Post-Bariatric Copper Deficiency Myelopathy

The second major cause of copper-deficiency myelopathy in adults is bariatric surgery, particularly Roux-en-Y gastric bypass and biliopancreatic diversion with duodenal switch. These procedures bypass the duodenum and proximal jejunum, where dietary copper absorption is concentrated. The result is a 10–20% lifetime risk of copper deficiency over 5–10 years post-operatively, with some patients presenting decades after the original surgery.

The clinical picture is identical to the zinc-induced syndrome — progressive myelopathy with gait ataxia, sensory loss, spasticity, and concomitant cytopenias. The diagnostic clue is the surgical history. Bariatric programs now routinely prescribe prophylactic copper supplementation (~2 mg/day) and monitor copper status periodically, but many patients fall out of bariatric follow-up over time and present years later with established myelopathy.

Recovery after diagnosis and treatment is similar across causes: hematologic indices usually normalize within weeks to months of copper repletion, but neurologic recovery is often partial because axonal demyelination has already occurred. Early diagnosis (before significant neurologic deficit) is therefore the highest-yield clinical intervention.

Back to Table of Contents

Mimicking B12 Subacute Combined Degeneration

Copper-deficiency myelopathy is the textbook mimic of Vitamin B12 deficiency subacute combined degeneration. The two syndromes are almost indistinguishable on clinical and radiographic grounds:

Critically, B12 supplementation in a copper-deficient patient does not improve the syndrome and may delay diagnosis. Any patient with suspected B12-deficiency myelopathy should also have copper, ceruloplasmin, and zinc measured at the same time. If B12 levels are normal or repletion fails to improve symptoms, copper status should be the next consideration.

The reverse mistake is equally important: a copper-deficient patient with concomitant B12 deficiency (the two can coexist, particularly in post-bariatric patients) needs both vitamins replaced. The hematologic improvement from B12 alone may mask the persistent copper-deficient neurologic syndrome.

Back to Table of Contents

Menkes Disease Neurology

Menkes disease, the X-linked recessive disorder caused by loss-of-function ATP7A mutations described on the Connective Tissue page, produces a devastating infantile encephalopathy that demonstrates the simultaneous failure of multiple copper-dependent enzymes in the developing brain:

Treatment with subcutaneous copper-histidine, started in the first weeks of life (before significant brain copper accumulation has been missed), can extend survival and partially preserve neurologic function in some milder ATP7A variants. The intervention requires neonatal screening (currently performed in a small number of pilot programs) because the diagnostic window is so narrow — by the time the classical kinky-hair phenotype appears at 2–4 months of age, the brain copper deficit is usually too advanced to fully reverse.

Back to Table of Contents

Copper, Alzheimer Disease, and Parkinson Disease

The role of copper in neurodegenerative disease is an active area of research and a source of substantial controversy. Two propositions are reasonably well-established:

  1. Total brain copper content is altered in Alzheimer disease and Parkinson disease tissue — with some studies finding reduced copper in surviving neurons and others finding elevated copper in plaques and Lewy bodies. The data are heterogeneous.
  2. Elevated bioavailable (non-ceruloplasmin) copper in plasma is associated with Alzheimer disease in cross-sectional studies (Squitti et al., meta-analyses). The "non-ceruloplasmin copper" is the loosely-bound serum copper that is not on its protein chaperone; some authors interpret this as evidence of copper dyshomeostasis in Alzheimer disease.

The mechanistic proposals are several:

The therapeutic implications are unsettled. Copper chelation (PBT2, an 8-hydroxyquinoline copper/zinc ionophore) was tested in Alzheimer disease in IMAGINE and other trials with mixed results. Copper supplementation in AD has not been studied rigorously. The conservative clinical position is that adequate but not supraphysiologic copper status is desirable in cognitive aging, and that copper supplementation in patients with normal copper status is not warranted on current evidence.

For more on these conditions, see our pages on Alzheimer Disease and Parkinson Disease.

Back to Table of Contents

Diagnosis and Treatment

The clinical workup for suspected copper-deficiency myelopathy:

Treatment principles:

Back to Table of Contents

Key Research Papers

  1. Schleper B, Stuerenburg HJ (2001). Copper deficiency-associated myelopathy in a 46-year-old woman. Journal of Neurology. — PubMed
  2. Kumar N, Gross JB Jr, Ahlskog JE (2003). Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration. Neurology. — PubMed
  3. Jaiser SR, Winston GP (2010). Copper deficiency myelopathy. Journal of Neurology. — PubMed
  4. Nations SP et al. (2008). Denture cream: an unusual source of excess zinc, leading to hypocupremia and neurologic disease. Neurology. — PubMed
  5. Hedera P et al. (2003). Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown origin. Neurology. — PubMed
  6. Spinazzi M et al. (2007). Myelo-optico-neuropathy in copper deficiency occurring after partial gastrectomy. Journal of Neurology. — PubMed
  7. Kaler SG (2011). ATP7A-related copper transport diseases — emerging concepts and future trends. Nature Reviews Neurology. — PubMed
  8. Squitti R et al. (2014). Meta-analysis of serum non-ceruloplasmin copper in Alzheimer's disease. Journal of Alzheimer's Disease. — PubMed
  9. Bush AI (2000). Metals and neuroscience. Current Opinion in Chemical Biology. — PubMed
  10. Robinson SR et al. (2003). Copper and brain function. Pharmacology & Therapeutics. — PubMed
  11. Senthilkumaran S et al. (2014). Copper deficiency myelopathy after Roux-en-Y gastric bypass. Indian Journal of Surgery. — PubMed
  12. Goyens P, Brasseur D, Cadranel S (1985). Copper deficiency in infants with active celiac disease. Journal of Pediatric Gastroenterology and Nutrition. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents